Page last updated: 2024-08-23

cicletanine and marinobufagenin

cicletanine has been researched along with marinobufagenin in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bagrov, AY; Dmitrieva, RI; Dorofeeva, NA; Droy-Lefaix, MT; Fedorova, OV; Lakatta, EG; Lopatin, DA	1
Agalakova, NI; Bagrov, AY; Droy-Lefaix, MT; Fedorova, OV; Lakatta, EG; Talan, MI	1

Other Studies

2 other study(ies) available for cicletanine and marinobufagenin

Article	Year
Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism. Journal of hypertension, 2000, Volume: 18, Issue:2 Topics: Animals; Antihypertensive Agents; Brain; Bufanolides; Cyclic GMP; Endothelin-1; Enzyme Inhibitors; Humans; In Vitro Techniques; Male; Mesenteric Arteries; Middle Aged; Protein Kinase C; Pyridines; Rats; Sodium-Potassium-Exchanging ATPase; Vasoconstriction	2000
Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension. Hypertension (Dallas, Tex. : 1979), 2003, Volume: 41, Issue:3 Topics: Animals; Antihypertensive Agents; Binding Sites; Blood Pressure; Bufanolides; Enzyme Inhibitors; Heart Ventricles; Hypertension; Hypertrophy, Left Ventricular; Kidney; Protein Kinase C; Protein Kinase C beta; Pyridines; Rats; Rats, Inbred Dahl; Sarcolemma; Sodium-Potassium-Exchanging ATPase	2003

Article

Year

Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism.

Journal of hypertension, 2000, Volume: 18, Issue:2

Topics: Animals; Antihypertensive Agents; Brain; Bufanolides; Cyclic GMP; Endothelin-1; Enzyme Inhibitors; Humans; In Vitro Techniques; Male; Mesenteric Arteries; Middle Aged; Protein Kinase C; Pyridines; Rats; Sodium-Potassium-Exchanging ATPase; Vasoconstriction

2000

Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension.

Hypertension (Dallas, Tex. : 1979), 2003, Volume: 41, Issue:3

Topics: Animals; Antihypertensive Agents; Binding Sites; Blood Pressure; Bufanolides; Enzyme Inhibitors; Heart Ventricles; Hypertension; Hypertrophy, Left Ventricular; Kidney; Protein Kinase C; Protein Kinase C beta; Pyridines; Rats; Rats, Inbred Dahl; Sarcolemma; Sodium-Potassium-Exchanging ATPase

2003